Outcomes and characteristics of ertapenem-nonsusceptible Klebsiella pneumoniae bacteremia at a university hospital in Northern Taiwan: A matched case-control study

Journal of Microbiology, Immunology and Infection

Volumn 45, Issue 2, 2012, Pages 113-119

  Liu, Shi Wei ^a   Chang, Hong Jyun ^a   Chia, Ju Hsin ^b   Kuo, An Jing ^b   Wu, Tsu Lan ^b   Lee, Ming Hsun ^a  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^b CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

Bacteremia; Ertapenem nonsusceptible; Klebsiella pneumoniae

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMOXICILLIN; ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE INHIBITOR; CARBAPENEM DERIVATIVE; CEPHALOSPORIN DERIVATIVE; CLINDAMYCIN; ERTAPENEM; METRONIDAZOLE; OXACILLIN; PIPERACILLIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ACUTE KIDNEY FAILURE; ADULT; AGED; ANTIBIOTIC SENSITIVITY; ARTICLE; ARTIFICIAL VENTILATION; BACTEREMIA; CENTRAL VENOUS CATHETER; CHRONIC KIDNEY DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EXPOSURE; FEMALE; HUMAN; INDWELLING CATHETER; INTENSIVE CARE UNIT; KLEBSIELLA PNEUMONIAE; LENGTH OF STAY; MALE; MORTALITY; NONHUMAN; OUTCOME ASSESSMENT; PITTSBURGH BACTEREMIA SCORE; RISK FACTOR; SCORING SYSTEM; TAIWAN; UNIVERSITY HOSPITAL;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BACTEREMIA; BETA-LACTAM RESISTANCE; BETA-LACTAMS; CASE-CONTROL STUDIES; FEMALE; HOSPITALS, UNIVERSITY; HUMANS; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; MALE; MIDDLE AGED; RISK FACTORS; SURVIVAL ANALYSIS; TAIWAN; TREATMENT OUTCOME;

EID: 84859836779     PISSN: 16841182     EISSN: 19959133     Source Type: Journal    
DOI: 10.1016/j.jmii.2011.09.026     Document Type: Article

References (25)

1. Endimiani A., Luzzaro F., Perilli M., Lombardi G., Coli A., Tamborini A., et al. Bacteremia due to Klebsiella pneumoniae isolates producing the TEM-52 extended spectrum β-lactamases: treatment outcome of patients receiving imipenem or ciprofloxacin. Clin Infect Dis 2004, 38:243-251.
2. MacKenzie F.M., Forbes K.J., Dorai-John T., Amyes S.G., Gould I.M. Emergence of a carbapenem-resistant Klebsiella pneumoniae. Lancet 1997, 350:783.
3. Koh T.H., Babini G.S., Woodford N., Sng L.H., Hall L.M., Livermore D.M. Carbapenem hydrolyzing IMP-1 β-lactamase in Klebsiella pneumoniae from Singapore. Lancet 1999, 353:2162.
4. Lincopan N., McCulloch J.A., Reinert C., Cassettari V.C., Gales A.C., Mamizuka E.M. First isolation of metallo-β-lactamase-producing multiresistant Klebsiella pneumoniae from a patient in Brazil. J Clin Microbiol 2005, 43:516-519.
5. Bradford P.A., Bratu S., Urban C., Visalli M., Mariano N., Landman D., et al. Emergence of carbapenem-resistant Klebsiella species possessing the class A carbapenem-hydrolyzing KPC-2 and inhibitor-resistant TEM-30 beta-lactamases in New York City. Clin Infect Dis 2004, 39:55-60.
6. Yigit H., Queenan A.M., Anderson G.J., Domenech-Sanchez A., Biddle J.W., Steward C.D., et al. Novel carbapenem-hydrolyzing beta-lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniae. Antimicrob Agents Chemother 2001, 45(4):1151-1161.
7. Bratu S., Landman D., Haag R., Recco R., Eramo A., Alam M., et al. Rapid spread of carbapenem-resistant Klebsiella pneumoniae in New York City: a new threat to our antibiotic armamentarium. Arch. Intern. Med 2005, 165:1430-1435.
8. Woodford N., Tierno P.M., Young K., Tysall L., Palepou M.F., Ward E., et al. Outbreak of Klebsiella pneumoniae producing a new carbapenem-hydrolyzing class A β-lactamase, KPC-3, in a New York medical center. Antimicrob Agents Chemother 2004, 48:4793-4799.
9. Yigit H., Queenan A.M., Rasheed J.K., Biddle J.W., Domenech-Sanchez A., Alberti S., et al. Carbapenem-resistant strain of Klebsiella oxytoca harboring carbapenem-hydrolyzing beta-lactamase KPC-2. Antimicrob Agents Chemother 2003, 47:3881-3889.
10. Leavitt A., Navon-Venezia S., Chmelnitsky I., Schwaber M.J., Carmeli Y. Emergence of KPC-2 and KPC-3 in carbapenem-resistant Klebsiella pneumoniae strains in an Israeli hospital. Antimicrob Agents Chemother 2007, 51:3026-3029.
11. Samra Z., Ofir O., Lishtzinsky Y., Madar-Shapiro L., Bishara J. Outbreak of carbapenem-resistant Klebsiella pneumoniae producing KPC-3 in a tertiary medical centre in Israel. Int J Antimicrob Agents 2007, 30:525-529.
12. Schwaber M.J., Klarfeld-Lidji S., Navon-Venezia S., Schwartz D., Leavitt A., Carmeli Y. Predictors of carbapenem-resistant Klebsiella pneumoniae acquisition among hospitalized adults and effect of acquisition on mortality. Antimicrob Agents Chemother 2008, 52:1028-1033.
13. Kumarasamy K.K., Toleman M.A., Walsh T.R., Bagaria J., Butt F., Balakrishnan R., et al. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. Lancet Infect Dis 2010, 10:597-602.
14. Hoban D.J., Bouchillon S.K., Hawser S.P., Badal R.E. Trends in the frequency of multiple drug-resistant Enterobacteriaceae and their susceptibility to ertapenem, imipenem, and other antimicrobial agents: data from the Study for Monitoring Antimicrobial Resistance Trends 2002 to 2007. Diagn Microbiol Infect Dis 2010, 66:78-86.
15. Kwak Y.G., Choi S.H., Choo E.J., Chung J.W., Jeong J.Y., Kim N.J., et al. Risk factors for the acquisition of carbapenem-resistant Klebsiella pneumoniae among hospitalized patients. Microb Drug Resist 2005, 11:165-169.
16. Falagas M.E., Rafailidis P.I., Kofteridis D., Virtzili S., Chelvatzoglou F.C., Papaioannou V., et al. Risk factors of carbapenem-resistant Klebsiella pneumoniae infections: a matched case control study. J Antimicrob Chemother 2007, 60:1124-1130.
17. Patel G., Huprikar S., Factor S.H., Jenkins S.G., Calfee D.P. Outcomes of carbapenem-resistant Klebsiella pneumoniae infection and the impact of antimicrobial and adjunctive therapies. Infect Control Hosp Epidemiol 2008, 29:1099-1106.
18. Hussein K., Sprecher H., Mashiach T., Oren I., Kassis I., Finkelstein R. Carbapenem resistance among Klebsiella pneumoniae isolates: risk factors, molecular characteristics, and susceptibility patterns. Infect Control Hosp Epidemiol 2009, 30:666-671.
19. Gasink L.B., Edelstein P.H., Lautenbach E., Synnestvedt M., Fishman N.O. Risk factors and clinical impact of Klebsiella pneumoniae carbapenemase-producing K pneumoniae. Infect Control Hosp Epidemiol 2009, 30:1180-1185.
20. Rhee J.Y., Kwon K.T., Ki H.K., Shin S.Y., Jung D.S., Chung D.R., et al. Scoring systems for prediction of mortality in patients with intensive care unit-acquired sepsis: a comparison of the Pitt bacteremia score and the acute physiology and chronic health evaluation II scoring systems. Shock 2009, 31:146-150.
21. Performance standards for antimicrobial disk susceptibility tests; approved standard M02-A10 2009, Clinical and Laboratory Standards Institute, CLSI, Wayne, PA, USA. 10th ed.
22. Performance standards for antimicrobial susceptibility testing; nineteen informational supplement: M100-S19 2009, Clinical and Laboratory Standards Institute, CLSI, Wayne, PA, USA.
23. Siddiqi A., Sethi S. Optimizing antibiotic selection in treating COPD exacerbations. Int J Chron Obstruct Pulmon Dis 2008, 3:31-44.
24. Borer A., Saidel-Odes L., Riesenberg K., Eskira S., Peled N., Nativ R., et al. Attributable mortality rate for carbapenem-resistant Klebsiella pneumoniae bacteremia. Infect Control Hosp Epidemiol 2009, 30:972-976.
25. Leavitt A., Chmelnitsky I., Colodner R., Ofek I., Carmeli Y., Navon-Venezia S. Ertapenem resistance among extended-spectrum-β-lactamase-producing Klebsiella pneumoniae isolates. J Clin Microbiol 2009, 47:969-974.